HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Raises Price Target to $22
Author: Benzinga Newsdesk | October 29, 2025 06:07am
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and raises the price target from $9 to $22.